Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients.

@article{Gmez1992IncidenceOL,
  title={Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients.},
  author={Jos{\'e} Luis Santos G{\'o}mez and Andr{\'e} Dupont and Leonello Cusan and M. D. Tremblay and Raul Suburu and Michel Lemay and Fernand Labrie},
  journal={The American journal of medicine},
  year={1992},
  volume={92 5},
  pages={465-70}
}
PURPOSE The incidence of flutamide-related liver toxicity was studied in 1,091 consecutive patients treated for stage C or D prostate cancer with the antiandrogen flutamide and the luteinizing hormone-releasing factor (LHRH) agonist [D-Trp6, des-Gly-NH2(10)] LHRH ethylamide. PATIENTS AND METHODS Liver function tests, namely measurement of serum aspartate amino-transferase (AST) and alanine aminotransferase (ALT), total bilirubin, alkaline phosphatase, gamma-glutamyl transpeptidase (gamma-GT… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
The incidence of flutamide - related liver toxicity was studied in 1,091 consecutive patients treated for stage C or D prostate cancer with the antiandrogen flutamide and the luteinizing hormone - releasing factor ( LHRH ) agonist [ D - Trp6 , des - Gly - NH2(10 ) ] LHRH ethylamide .
The incidence of flutamide - related liver toxicity was studied in 1,091 consecutive patients treated for stage C or D prostate cancer with the antiandrogen flutamide and the luteinizing hormone - releasing factor ( LHRH ) agonist [ D - Trp6 , des - Gly - NH2(10 ) ] LHRH ethylamide .
The incidence of flutamide - related liver toxicity was studied in 1,091 consecutive patients treated for stage C or D prostate cancer with the antiandrogen flutamide and the luteinizing hormone - releasing factor ( LHRH ) agonist [ D - Trp6 , des - Gly - NH2(10 ) ] LHRH ethylamide .
The incidence of flutamide - related liver toxicity was studied in 1,091 consecutive patients treated for stage C or D prostate cancer with the antiandrogen flutamide and the luteinizing hormone - releasing factor ( LHRH ) agonist [ D - Trp6 , des - Gly - NH2(10 ) ] LHRH ethylamide .
The incidence of flutamide - related liver toxicity was studied in 1,091 consecutive patients treated for stage C or D prostate cancer with the antiandrogen flutamide and the luteinizing hormone - releasing factor ( LHRH ) agonist [ D - Trp6 , des - Gly - NH2(10 ) ] LHRH ethylamide .
The incidence of flutamide - related liver toxicity was studied in 1,091 consecutive patients treated for stage C or D prostate cancer with the antiandrogen flutamide and the luteinizing hormone - releasing factor ( LHRH ) agonist [ D - Trp6 , des - Gly - NH2(10 ) ] LHRH ethylamide .
The incidence of flutamide - related liver toxicity was studied in 1,091 consecutive patients treated for stage C or D prostate cancer with the antiandrogen flutamide and the luteinizing hormone - releasing factor ( LHRH ) agonist [ D - Trp6 , des - Gly - NH2(10 ) ] LHRH ethylamide .
The incidence of flutamide - related liver toxicity was studied in 1,091 consecutive patients treated for stage C or D prostate cancer with the antiandrogen flutamide and the luteinizing hormone - releasing factor ( LHRH ) agonist [ D - Trp6 , des - Gly - NH2(10 ) ] LHRH ethylamide .
The incidence of flutamide - related liver toxicity was studied in 1,091 consecutive patients treated for stage C or D prostate cancer with the antiandrogen flutamide and the luteinizing hormone - releasing factor ( LHRH ) agonist [ D - Trp6 , des - Gly - NH2(10 ) ] LHRH ethylamide .
The incidence of flutamide - related liver toxicity was studied in 1,091 consecutive patients treated for stage C or D prostate cancer with the antiandrogen flutamide and the luteinizing hormone - releasing factor ( LHRH ) agonist [ D - Trp6 , des - Gly - NH2(10 ) ] LHRH ethylamide .
The incidence of flutamide - related liver toxicity was studied in 1,091 consecutive patients treated for stage C or D prostate cancer with the antiandrogen flutamide and the luteinizing hormone - releasing factor ( LHRH ) agonist [ D - Trp6 , des - Gly - NH2(10 ) ] LHRH ethylamide .
The incidence of flutamide - related liver toxicity was studied in 1,091 consecutive patients treated for stage C or D prostate cancer with the antiandrogen flutamide and the luteinizing hormone - releasing factor ( LHRH ) agonist [ D - Trp6 , des - Gly - NH2(10 ) ] LHRH ethylamide .
The incidence of flutamide - related liver toxicity was studied in 1,091 consecutive patients treated for stage C or D prostate cancer with the antiandrogen flutamide and the luteinizing hormone - releasing factor ( LHRH ) agonist [ D - Trp6 , des - Gly - NH2(10 ) ] LHRH ethylamide .
The incidence of flutamide - related liver toxicity was studied in 1,091 consecutive patients treated for stage C or D prostate cancer with the antiandrogen flutamide and the luteinizing hormone - releasing factor ( LHRH ) agonist [ D - Trp6 , des - Gly - NH2(10 ) ] LHRH ethylamide .
The incidence of flutamide - related liver toxicity was studied in 1,091 consecutive patients treated for stage C or D prostate cancer with the antiandrogen flutamide and the luteinizing hormone - releasing factor ( LHRH ) agonist [ D - Trp6 , des - Gly - NH2(10 ) ] LHRH ethylamide .
FlutamideContraindicated with diseaseLiver diseases
The incidence of flutamide - related liver toxicity was studied in 1,091 consecutive patients treated for stage C or D prostate cancer with the antiandrogen flutamide and the luteinizing hormone - releasing factor ( LHRH ) agonist [ D - Trp6 , des - Gly - NH2(10 ) ] LHRH ethylamide .
Despite the fact that the cases reported so far , along with our large series , indicate that the incidence of flutamide - induced liver toxicity is very low , we recommend serial blood aminotransferase measurements at 2 and 4 weeks of treatment in order to detect early signs of possible flutamide - induced hepatic injury , thus avoiding the low potential risk of clinically significant liver toxicity .
Despite the fact that the cases reported so far , along with our large series , indicate that the incidence of flutamide - induced liver toxicity is very low , we recommend serial blood aminotransferase measurements at 2 and 4 weeks of treatment in order to detect early signs of possible flutamide - induced hepatic injury , thus avoiding the low potential risk of clinically significant liver toxicity .
Despite the fact that the cases reported so far , along with our large series , indicate that the incidence of flutamide - induced liver toxicity is very low , we recommend serial blood aminotransferase measurements at 2 and 4 weeks of treatment in order to detect early signs of possible flutamide - induced hepatic injury , thus avoiding the low potential risk of clinically significant liver toxicity .
Despite the fact that the cases reported so far , along with our large series , indicate that the incidence of flutamide - induced liver toxicity is very low , we recommend serial blood aminotransferase measurements at 2 and 4 weeks of treatment in order to detect early signs of possible flutamide - induced hepatic injury , thus avoiding the low potential risk of clinically significant liver toxicity .
The incidence of flutamide - related liver toxicity was studied in 1,091 consecutive patients treated for stage C or D prostate cancer with the antiandrogen flutamide and the luteinizing hormone - releasing factor ( LHRH ) agonist [ D - Trp6 , des - Gly - NH2(10 ) ] LHRH ethylamide .
All clinical and biologic manifestations of liver toxicity rapidly disappeared upon discontinuation of flutamide alone .
Liver function tests , namely measurement of serum aspartate amino - transferase ( AST ) and alanine aminotransferase ( ALT ) , total bilirubin , alkaline phosphatase , gamma - glutamyl transpeptidase ( gamma - GT ) , and prothrombin and thromboplastin times , were performed at 4 , 8 , and 12 weeks and every 3 months thereafter .
Liver function tests , namely measurement of serum aspartate amino - transferase ( AST ) and alanine aminotransferase ( ALT ) , total bilirubin , alkaline phosphatase , gamma - glutamyl transpeptidase ( gamma - GT ) , and prothrombin and thromboplastin times , were performed at 4 , 8 , and 12 weeks and every 3 months thereafter .
Liver function tests , namely measurement of serum aspartate amino - transferase ( AST ) and alanine aminotransferase ( ALT ) , total bilirubin , alkaline phosphatase , gamma - glutamyl transpeptidase ( gamma - GT ) , and prothrombin and thromboplastin times , were performed at 4 , 8 , and 12 weeks and every 3 months thereafter .
Liver function tests , namely measurement of serum aspartate amino - transferase ( AST ) and alanine aminotransferase ( ALT ) , total bilirubin , alkaline phosphatase , gamma - glutamyl transpeptidase ( gamma - GT ) , and prothrombin and thromboplastin times , were performed at 4 , 8 , and 12 weeks and every 3 months thereafter .
The incidence of flutamide - related liver toxicity was studied in 1,091 consecutive patients treated for stage C or D prostate cancer with the antiandrogen flutamide and the luteinizing hormone - releasing factor ( LHRH ) agonist [ D - Trp6 , des - Gly - NH2(10 ) ] LHRH ethylamide .
Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients .
The incidence of flutamide - related liver toxicity was studied in 1,091 consecutive patients treated for stage C or D prostate cancer with the antiandrogen flutamide and the luteinizing hormone - releasing factor ( LHRH ) agonist [ D - Trp6 , des - Gly - NH2(10 ) ] LHRH ethylamide .
The incidence of flutamide - related liver toxicity was studied in 1,091 consecutive patients treated for stage C or D prostate cancer with the antiandrogen flutamide and the luteinizing hormone - releasing factor ( LHRH ) agonist [ D - Trp6 , des - Gly - NH2(10 ) ] LHRH ethylamide .
The incidence of flutamide - related liver toxicity was studied in 1,091 consecutive patients treated for stage C or D prostate cancer with the antiandrogen flutamide and the luteinizing hormone - releasing factor ( LHRH ) agonist [ D - Trp6 , des - Gly - NH2(10 ) ] LHRH ethylamide .
The causal link between the antiandrogen used and liver injury was assessed on the basis of the temporal relationship with the use of the drug in the absence of other possible causes and , in two patients , through rechallenge of the putative causative drug after a period of normalization of liver function .
Despite the fact that the cases reported so far , along with our large series , indicate that the incidence of flutamide - induced liver toxicity is very low , we recommend serial blood aminotransferase measurements at 2 and 4 weeks of treatment in order to detect early signs of possible flutamide - induced hepatic injury , thus avoiding the low potential risk of clinically significant liver toxicity .
Despite the fact that the cases reported so far , along with our large series , indicate that the incidence of flutamide - induced liver toxicity is very low , we recommend serial blood aminotransferase measurements at 2 and 4 weeks of treatment in order to detect early signs of possible flutamide - induced hepatic injury , thus avoiding the low potential risk of clinically significant liver toxicity .
Despite the fact that the cases reported so far , along with our large series , indicate that the incidence of flutamide - induced liver toxicity is very low , we recommend serial blood aminotransferase measurements at 2 and 4 weeks of treatment in order to detect early signs of possible flutamide - induced hepatic injury , thus avoiding the low potential risk of clinically significant liver toxicity .
Despite the fact that the cases reported so far , along with our large series , indicate that the incidence of flutamide - induced liver toxicity is very low , we recommend serial blood aminotransferase measurements at 2 and 4 weeks of treatment in order to detect early signs of possible flutamide - induced hepatic injury , thus avoiding the low potential risk of clinically significant liver toxicity .
Despite the fact that the cases reported so far , along with our large series , indicate that the incidence of flutamide - induced liver toxicity is very low , we recommend serial blood aminotransferase measurements at 2 and 4 weeks of treatment in order to detect early signs of possible flutamide - induced hepatic injury , thus avoiding the low potential risk of clinically significant liver toxicity .
Despite the fact that the cases reported so far , along with our large series , indicate that the incidence of flutamide - induced liver toxicity is very low , we recommend serial blood aminotransferase measurements at 2 and 4 weeks of treatment in order to detect early signs of possible flutamide - induced hepatic injury , thus avoiding the low potential risk of clinically significant liver toxicity .
All Topics